SCHEMBL9984679

SCHEMBL9984679

N1=C(c2nnc(-c3nn[nH]n3)nn2)NNN1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 2/20 0.38
CYP3A4 P08684 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ADH5 P11766 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HCAR2 Q8TDS4 6/20 0.33
USP2 O75604 1/20 0.33
RPA1 P27694 1/20 0.32
ATM Q13315 1/20 0.32
HCAR3 P49019 1/20 0.31
PBRM1 Q86U86 1/20 0.31
IDO1 P14902 1/20 0.31
GAA P10253 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LDHA P00338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9985471 0.71 ALDH1A1 (0.62) ALDH1A1ALOX15CYP3A4HIF1AHSD17B10
SCHEMBL7196747 0.60 ALDH1A1 (0.41) ALDH1A1ALOX15CYP3A4HIF1AHSD17B10
SCHEMBL15849789 0.56 ADH5 (0.68) ALDH1A1HSD17B10ADH5MEN1KMT2A
SCHEMBL9984638 0.56 ADH5 (0.95) ALDH1A1ADH5MEN1KMT2AL3MBTL1
SCHEMBL10111979 0.53 ATM (0.44) ALDH1A1ALOX15CYP3A4HIF1AHSD17B10
SCHEMBL2932335 0.50 ADH5 (0.71) ALDH1A1ADH5MEN1KMT2AL3MBTL1
SCHEMBL4983079 0.50 HPGDS (0.75) ALDH1A1ADH5MEN1KMT2AL3MBTL1
SCHEMBL29215854 0.50
SCHEMBL19403602 0.49 ALDH1A1 (0.42) ALDH1A1CYP3A4HSD17B10MEN1KMT2A
SCHEMBL14347139 0.49 ADH5 (0.75) ALDH1A1HSD17B10ADH5RPA1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9918964-B2 Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-03-20 US disclosed
US-9918964-B2 Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-03-20 US disclosed
US-9918964-B2 Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2018-03-20 US disclosed
US-20110301180-A1 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration STANFORD UNIVERSITY (US) 2011-12-08 US disclosed
US-20110301180-A1 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration STANFORD UNIVERSITY (US) 2011-12-08 US disclosed
US-20110301180-A1 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration STANFORD UNIVERSITY (US) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301180-A1 Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration PC, PFKP, UQCRC1 ALDH1A1 1585/4885ALOX15 319/4885CYP3A4 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.